Remarkably, from this rather limited panel of antibodies, the mAb targeting DR4, C#16, and the anti-DR5, C#22, were both able to partially reduce, alone, the cell viability of the colorectal cancer cell line HCT116, in a dose-dependent manner (Fig. 2a). The gene discussed is TNFRSF10A; the disease is colorectal cancer.